Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Exp Rheumatol ; 36 Suppl 113(4): 175-182, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30277867

RESUMO

There are no Federal Drug Administration approved drugs for the treatment of systemic sclerosis vascular digital ulcers (DU) in the United States, which are thought to be an end-stage result of prolonged ischaemia due to severe, prolonged Raynaud's phenomenon. Most therapeutics for vasodilation used in SSc work different pathways to target the smooth muscle to induce vessel relaxation. Longitudinal studies of vascular function allow insight into the effects of medications used for Raynaud's phenomenon in the SSc patient population. In this review, we discuss vascular tone, the function of the endothelium in SSc, and provide the rationale for longitudinal studies of vascular function and therapeutics that target the endothelial shear stress in addition to vasodilation for treatment and prevention of DU. This review provides the rationale for vasodilatory medication use for treatment of SSc-related DU and justifies access to non-FDA approved medications for this indication.


Assuntos
Endotélio Vascular/fisiopatologia , Mãos/irrigação sanguínea , Microcirculação , Doença de Raynaud/fisiopatologia , Escleroderma Sistêmico/fisiopatologia , Úlcera Cutânea/fisiopatologia , Vasodilatação , Animais , Endotélio Vascular/efeitos dos fármacos , Humanos , Microcirculação/efeitos dos fármacos , Doença de Raynaud/diagnóstico , Doença de Raynaud/tratamento farmacológico , Doença de Raynaud/etiologia , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/diagnóstico , Escleroderma Sistêmico/tratamento farmacológico , Úlcera Cutânea/diagnóstico , Úlcera Cutânea/tratamento farmacológico , Úlcera Cutânea/etiologia , Estresse Mecânico , Resultado do Tratamento , Vasodilatação/efeitos dos fármacos , Vasodilatadores/uso terapêutico
2.
Cell Tissue Bank ; 17(3): 413-25, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27460879

RESUMO

Amniotic fluid (AF) possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications. The goals of this study were to assess the feasibility of collecting AF from full-term pregnancies and to evaluate non-cellular and cellular properties of AF for clinical applications. Donor informed consent and medical histories were obtained from pregnant women scheduled for C-sections and infectious disease testing was performed the day of collection. AFs were evaluated for total volume, fluid chemistries, total protein, and hyaluronic acid (HA) levels. AF was also assessed with quantitative antibody arrays, cellular content and for an ability to support angiogenesis. Thirty-six pregnant women consented and passed donor screening to give birth tissue. AF was successfully collected from 17 individuals. Median AF volumes were 70 mL (range 10-815 mL; n = 17). Fluid chemistries were similar, but some differences were noted in HA levels and cytokine profiles. Cytokine arrays revealed that an average of 304 ± 20 of 400 proteins tested were present in AF with a majority of cytokines associated with host defense. AF supported angiogenesis. Epithelioid cells were the major cell type in AF with only a minor population of lymphoid cells. Cultures revealed a highly proliferative population of adherent cells capable of producing therapeutic doses of mesenchymal stromal cells (MSCs). These findings showed that significant volumes of AF were routinely collected from full-term births. AF contained a number of bioactive proteins and only a rare population of MSCs. Variations noted in components present in different AFs, warrant further investigations to determine their relevance for specific clinical applications.


Assuntos
Líquido Amniótico/citologia , Cesárea , Manejo de Espécimes/métodos , Adesão Celular , Proliferação de Células , Análise por Conglomerados , Citocinas/metabolismo , Células Endoteliais/fisiologia , Feminino , Humanos , Células-Tronco Mesenquimais/citologia , Fenótipo , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA